Biotime has been quietly generating monstrous profits for its shareholders, unbeknownst to most of Wall Street and tech-knowledgeable individual investors, as evidenced by its absence
here at SI. The stock has proven to be a 'ten-bagger' (from $2 to $22) within time period of just under two months, and all this (strangely) on an average daily volume of approximately 45,000!
Biotme holds the patents to Hextend, a plasma substitute used in any number of circumstances during which blood replacement is called for. This includes surgery, cryosurgery, and as a medium for preserving organs in organ banks. Hextend is only half the cost of whole blood and, of course, is a lot safer (no HIV, Hep, etc.)
Blood substitutes constitute a 5 billion dollar/year industry, and this means enormous earnings potential for Biotime.
FDA approval sanctioning the commencement of Hextend Phase III clinical trials is expected to be announced soon. The product is expected t0 be marketed within 2 to 3 years, making this a long play. |
